IMA Group Expands Clinical Research Division with Acquisition of Chicago Research Center

What's Happening?

The IMA Group has announced the acquisition of the Chicago Research Center (CRC), a clinical research site based in Chicago. This acquisition is part of IMA's strategy to expand its national footprint in clinical research, particularly in the areas of central nervous system (CNS) and sleep disorders. CRC, founded in 2005, is known for its expertise in Phase I-IV trials, focusing on CNS, sleep disorders, mood and memory disorders, pain, and general medicine. The facility includes a six-bed sleep lab and has conducted over 125 studies supported by a database of more than 50,000 patients. The acquisition marks IMA's first entry into sleep research, addressing a significant public health need as sleep disorders affect millions of Americans. CRC will continue to operate under its current name and leadership, with President and CEO Stacy Malm remaining at the helm.

Why It's Important?

The acquisition of CRC by IMA Group is significant as it enhances IMA's capabilities in conducting clinical trials for CNS and sleep disorders, areas that are increasingly important given the prevalence of these conditions in the U.S. According to the CDC, a substantial portion of the adult population suffers from inadequate sleep, which can lead to various health issues. By expanding its research capacity, IMA aims to accelerate the development of innovative treatments for these disorders, potentially improving patient outcomes and addressing unmet medical needs. This move also strengthens IMA's position in the clinical research industry, allowing it to offer more diverse and comprehensive services to sponsors and patients nationwide.

What's Next?

Following the acquisition, IMA Group plans to integrate CRC's expertise into its broader clinical research operations, potentially expanding sleep research across additional sites. This strategic expansion could lead to increased trial capacity and diversity, enhancing IMA's ability to conduct comprehensive studies in CNS and sleep disorders. The acquisition is part of IMA's ongoing efforts to grow its national platform, which includes nine clinical research acquisitions over the past four years. As IMA continues to expand, it may further strengthen its relationships with sponsors and contribute to the development of therapies for urgent health needs.

Beyond the Headlines

The acquisition of CRC by IMA Group highlights the growing importance of sleep research in addressing public health challenges. Sleep disorders are linked to various health issues, including mental health conditions, which are increasingly recognized as critical areas for research and treatment. By expanding its focus on sleep research, IMA is not only addressing a pressing health need but also contributing to the broader understanding of how sleep impacts overall health and well-being. This move could lead to long-term shifts in how sleep disorders are studied and treated, potentially influencing public health policy and clinical practices.